# Phase II Study of Arginine Butyrate With or Without Epoetin Alfa in Patients With Thalassemia Intermedia

> **NCT00006136** · PHASE2 · COMPLETED · sponsor: **Boston University** · enrollment: 15 (—)

## Conditions studied

- Beta-Thalassemia

## Interventions

- **DRUG:** arginine butyrate
- **DRUG:** epoetin alfa

## Key facts

- **NCT ID:** NCT00006136
- **Lead sponsor:** Boston University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-03
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 15 (—)
- **Last updated:** 2005-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00006136

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00006136, "Phase II Study of Arginine Butyrate With or Without Epoetin Alfa in Patients With Thalassemia Intermedia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00006136. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*